Wei Gao

ORCID: 0000-0002-5840-3609 · 5 papers in corpus · active 2020-2025

Study types

  • article 2
  • other 1
  • peer-review 1
  • preprint 1

Condition tags

  • endometriosis 3
  • infertility 1
preprint 2025
Diagnostic Pitfalls of Incarcerated Gravid Uterus: Report of Two Cases and Literature Review
·doi:10.21203/rs.3.rs-7601608/v1
other 2025
The association of activity patterns on female reproductive diseases: a prospective cohort study of UK biobank
BMC public health ·doi:10.1186/s12889-025-21576-z

OBJECTIVE: Little is known about the role of timing of physical activity in female reproductive disorders. These disorders include polycystic ovary syndrome (PCOS), heavy menstrual bleeding (HMB), endometriosis, infertility, and pregnancy-r…

article 2022
Interdisciplinary model‐informed drug development for extending duration of elagolix treatment in patients with uterine fibroids
·doi:10.1111/bcp.15440

AIM: Elagolix, a gonadotropin-releasing hormone receptor antagonist, was recently approved for heavy menstrual bleeding associated with uterine fibroids (UF, Oriahnn) at a dose of 300 mg twice daily (BID) in combination with add-back therap…

peer-review 2020
Author response for "Estimating the effect of elagolix treatment for endometriosis on post‐menopausal bone outcomes: a model bridging registrational phase III trials to an older real‐world population"
·doi:10.1002/jbm4.10401/v2/response1
article 2020
Estimating the Effect of Elagolix Treatment for Endometriosis on Postmenopausal Bone Outcomes: A Model Bridging Phase III Trials to an Older Real‐World Population
JBMR plus ·doi:10.1002/jbm4.10401

ABSTRACT Elagolix, a gonadotrophin‐releasing hormone antagonist, is used in premenopausal women with endometriosis. There is a risk of bone loss with elagolix, but the long‐term effects of BMD loss later in life cannot be directly assessed …